10.47

3.70% -0.4182

Arcus Biosciences Inc (RCUS)

Overview News Price History Option Chain Why RCUS Down? Discussions Forecast

Arcus Biosciences Inc stock is traded at $10.47, with a volume of 443.43K. It is down -3.70% in the last 24 hours and down -20.55% over the past month. Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Previous Close:

$10.89

Open:

$10.88

24h Volume:

443.43K

Relative Volume:

0.55

Market Cap:

$1.12B

Revenue:

$247.00M

Net Income/Loss:

$-249.00M

P/E Ratio:

-3.3889

EPS:

-3.09

Net Cash Flow:

$-267.00M

1W Performance:

+3.22%

1M Performance:

-20.55%

6M Performance:

-36.71%

1Y Performance:

-45.09%

1-Day Range:

$10.43

$11.10

1-Week Range:

$9.855

$11.68

52-Week Range:

$9.855

$19.69

Arcus Biosciences Inc Stock (RCUS) Company Profile

Name

Arcus Biosciences Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(510) 694-6200

Address

3928 POINT EDEN WAY, HAYWARD, CA

Employee

674

Twitter

@arcusbio

Next Earnings Date

2024-12-06

Latest SEC Filings

RCUS's Discussions on Twitter

Compare RCUS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
RCUS Arcus Biosciences Inc	10.47	1.12B	247.00M	-249.00M	-267.00M	-3.09
VRTX Vertex Pharmaceuticals Inc	490.11	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.45	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	632.13	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.19	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.67	27.34B	3.30B	-501.07M	1.03B	-2.1146

Arcus Biosciences Inc Stock (RCUS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-26-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-21-24	Initiated	H.C. Wainwright	Neutral
Oct-08-24	Initiated	Wells Fargo	Overweight
Nov-18-22	Initiated	BofA Securities	Neutral
Oct-11-22	Initiated	Morgan Stanley	Overweight
Oct-15-21	Resumed	BTIG Research	Buy
Nov-24-20	Initiated	Berenberg	Buy
Nov-23-20	Initiated	Evercore ISI	Outperform
Apr-03-20	Initiated	Cantor Fitzgerald	Overweight
Mar-04-20	Initiated	Barclays	Overweight
Nov-12-19	Initiated	SunTrust	Buy
Sep-27-19	Initiated	Mizuho	Buy
May-24-19	Resumed	Citigroup	Buy
Oct-09-18	Initiated	Wedbush	Outperform
Apr-09-18	Initiated	Citigroup	Buy
Apr-09-18	Initiated	Goldman	Neutral
Apr-09-18	Initiated	Leerink Partners	Outperform

View All

Arcus Biosciences Inc Stock (RCUS) Latest News

Mar 02, 2025

Insider Buying: Arcus Biosciences Co-Founder Bought US$201k Of Shares - Yahoo Canada Finance

Mar 02, 2025

Mar 01, 2025

Learn to Evaluate (RCUS) using the Charts - Stock Traders Daily

Mar 01, 2025

Feb 28, 2025

Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares By Investing.com - Investing.com South Africa

Feb 28, 2025

Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance UK

Feb 28, 2025

Feb 27, 2025

Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock By Investing.com - Investing.com South Africa

Feb 27, 2025

Arcus Biosciences director Yasunori Kaneko buys $201,200 in shares - Investing.com India

Feb 27, 2025

Arcus Biosciences CEO Terry J. Rosen buys $201,465 in common stock - Investing.com

Feb 27, 2025

RCUS stock touches 52-week low at $9.88 amid market challenges - Investing.com

Feb 27, 2025

Feb 26, 2025

Arcus Biosciences’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Feb 26, 2025

HC Wainwright & Co. Upgrades Arcus Biosciences (RCUS) - Nasdaq

Feb 26, 2025

Can Arcus Biosciences Reveal New Cancer Pipeline Updates at March Healthcare Conferences? - StockTitan

Feb 26, 2025

Arcus Biosciences' SWOT analysis: promising pipeline drives stock outlook - Investing.com

Feb 26, 2025

Arcus Biosciences gains after H.C. Wainwright upgrades to "buy" - TradingView

Feb 26, 2025

Arcus Biosciences Reports 2024 Financial Results and Pipeline Progress - TipRanks

Feb 26, 2025

Arcus Biosciences reports Q4 EPS ($1.03), consensus ($1.20) - TipRanks

Feb 26, 2025

Arcus Biosciences, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 26, 2025

Feb 25, 2025

Arcus Biosciences earnings beat by $0.20, revenue topped estimates - Investing.com Canada

Feb 25, 2025

Arcus Biosciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 25, 2025